L
Lucía Guillén
Researcher at Universidad Miguel Hernández de Elche
Publications - 8
Citations - 176
Lucía Guillén is an academic researcher from Universidad Miguel Hernández de Elche. The author has contributed to research in topics: Tocilizumab & Viral load. The author has an hindex of 4, co-authored 7 publications receiving 90 citations.
Papers
More filters
Journal ArticleDOI
Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study.
Mar Masiá,Marta Fernández-González,Sergio Padilla,Piedad Ortega,José A. García,Vanesa Agulló,Javier García-Abellán,Guillermo Telenti,Lucía Guillén,Félix Gutiérrez +9 more
TL;DR: The results suggest that in patients infected with SARS-CoV-2, IL-6 blockade does not impair the viral specific antibody responses, and the safety of this therapy in patients with COVID-19 is supported.
Journal ArticleDOI
SARS-CoV-2 seroconversion and viral clearance in patients hospitalized with COVID-19: viral load predicts antibody response
Mar Masiá,Guillermo Telenti,Marta S. Fernández,José A. García,Vanesa Agulló,Sergio Padilla,Javier García-Abellán,Lucía Guillén,Paula Mascarell,José C Asenjo,Félix Gutiérrez +10 more
TL;DR: In this paper, the authors investigated the viral determinants of antibody response, the predictors of nonseroconversion, and the role of antibodies on viral dynamics in patients with COVID-19.
Journal ArticleDOI
Preemptive interleukin-6 blockade in patients with COVID-19.
Lucía Guillén,Sergio Padilla,Marta S. Fernández,Vanesa Agulló,José A. García,Guillermo Telenti,Javier García-Abellán,Ángela Botella,Félix Gutiérrez,Mar Masiá +9 more
TL;DR: Preliminary results suggest that tocilizumab, a humanized monoclonal anti-interleukin-6 receptor antibody, may be beneficial in severely ill patients, but no data are available on earlier stages of disease.
Journal ArticleDOI
COVID-19-associated encephalitis successfully treated with combination therapy.
Eric Freire-Álvarez,Lucía Guillén,Karine Lambert,Ana Baidez,Miguel García-Quesada,María Andreo,Jordi Alom,Mar Masiá,Félix Gutiérrez +8 more
TL;DR: COVID-19 may present as an encephalitis syndrome mimicking acute demyelinating encephalomyelitis that could be amenable to therapeutic modulation, suggesting that it could be related to host inflammatory response.
Journal ArticleDOI
Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19.
Mar Masiá,Sergio Padilla,José A. García,Javier García-Abellán,Andrés Navarro,Lucía Guillén,Guillermo Telenti,Paula Mascarell,Ángela Botella,Félix Gutiérrez +9 more
TL;DR: Baricitinib is a Janus kinase (JAK) inhibitor with a broader anti-inflammatory activity than tocilizumab and an antiviral potential although no head-to-head trials are available.